Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Wenbing Duan, Qi Chen, WenJing Yu, Jinsong Jia, Jing Wang, Xiaolu Zhu, Ting Zhao, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Hongxia Shi, Ying-Jun Chang, Yu Wang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2024-206400

Published: 2024

Journal Articles

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Zongru Li, Lu Yu, Li-Juan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 6121.

https://doi.org/10.1182/blood-2024-211874

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2024-207269

Published: 2024

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Lizhong Gong, WenJing Yu, Xiaolu Zhu, Zhao Ting, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Yu Wang, Hongxia Shi, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4309.

https://doi.org/10.1182/blood-2023-184769

Published: 2023

Journal Articles

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Jing Wang, Siqi Li, Hao Jiang, Ying-Jun Chang, Xiao-su Zhao, Jinsong JIA, Xiaolu Zhu, Lizhong Gong, Xiaohong Liu, Wen-Jing Yu, Xiaojun Huang

Blood (2023) 142 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2023-174600

Published: 2023

Journal Articles

Prolonged Use of Eltrombopag in Patients with Severe Aplastic Anemia without Complete Response at 6 Months after Immunosuppressive Therapy

Ruixin Li, Qiqiang Long, Yan Yang, Shengyun Lin, Jinsong Jia, Donghua Zhang, Guangsheng He, Jianyong Li

Blood (2022) 140 (Supplement 1): 8650–8651.

https://doi.org/10.1182/blood-2022-165120

Published: 2022

Journal Articles

Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study

Xiaohong Liu, Yao Li, Wenjing Yu, Xiaolu Zhu, Jinsong Jia, Lizhong Gong, Xiaosu Zhao, Yingjun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2022) 140 (Supplement 1): 3299–3300.

https://doi.org/10.1182/blood-2022-168422

Published: 2022

Journal Articles

Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hui Liu, Linghui Xia, Jianyu Weng, Fengkui Zhang, Chuan He, Sujun Gao, Jinsong Jia, Alice C. Chang, Pontus Lundberg, Camelia S. Sima, Jane Shi, Zhenyu Xiao, Yuchen Zhang, Zilu Zhang, Rong Fu

Blood (2022) 140 (Supplement 1): 714–716.

https://doi.org/10.1182/blood-2022-162452

Published: 2022

Journal Articles

A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion

Ya-Lan Zhou, Yan Wei, Xiaohong Liu, Jing Wang, Jinsong Jia, Hong-Xia Shi, Ying-Jun Chang, Xiao-Su Zhao, Yan-Rong Liu, Guo-Rui Ruan, Xiao-Jun Huang, Hao Jiang

Blood (2021) 138 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2021-149623

Published: 2021

Journal Articles

Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience

Wen-Jing Yu, Jinsong JIA, Jing Wang, Fei-Fei Tang, Lizhong Gong, Xiaohong Liu, Xiaolu Zhu, Xiaosu Zhao, Xiao Jun Huang, Hao Jiang

Blood (2021) 138 (Supplement 1): 4413.

https://doi.org/10.1182/blood-2021-148259

Published: 2021

Journal Articles

Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy

Ruixin Li, Guangsheng He, Xi Chen, Zhengyuan Liu, Yan Yang, Shengyun Lin, Jinsong Jia, Yuanyuan Jin, Qiqiang Long, Xiaoqing Liu, Lang Cheng, Jiongtao Zhou, Jianyong Li

Blood (2021) 138 (Supplement 1): 1115.

https://doi.org/10.1182/blood-2021-152756

Published: 2021

Journal Articles

Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia

Ruixin Li, Yuanyuan Jin, Jinsong Jia, Shengyun Lin, Yan Yang, Guangsheng He, Jianyong Li

Blood (2021) 138 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2021-154361

Published: 2021

Journal Articles

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Hao Jiang, Jing Liu, Xiaohong Liu, Jinsong Jia, Lizhong Gong, Shengye Lu, Xiaojun Huang, Jing Wang, Xiaosu Zhao, Yueyun Lai, Hongxia Shi, Yingjun Chang, Guorui Ruan

Blood (2021) 138 (Supplement 1): 2320.

https://doi.org/10.1182/blood-2021-149493

Published: 2021

Journal Articles

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Jing Wang, MD, Jinsong Jia, Xiaohong Liu, Lizhong Gong, Shengye Lu, Yu Wang, Lanping Xu, Xiaohui Zhang, Chenhua Yan, Yueyun Lai, Xiaosu Zhao, PhD, Yazhen Qin, Guorui Ruan, Yingjun Chang, Hongxia Shi, Kaiyan Liu, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140977

Published: 2020

Journal Articles

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Wenbing Duan, Xiaohong Liu, Jinsong JIA, MDPhD, Jing Wang, MD, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, Lanping Xu, Xiaosu Zhao, PhD, Yazhen Qin, Hongxia Shi, Yingjun Chang, Xiaojun Huang, Hao Jiang, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141905

Published: 2020

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

Jinsong JIA, MD PhD, Hao Jiang, Xiao Jun Huang

Blood (2019) 134 (Supplement_1): 5019.

https://doi.org/10.1182/blood-2019-131670

Published: 2019

Journal Articles

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Wenbing Duan, Jinsong Jia, Jing Wang, MD, Xiaohong Liu, Lizhong Gong, Qian Jiang, MD, Ting Zhao, Yu Wang, Xiaohui Zhang, MD, Lanping Xu, Yanrong Liu, Yazhen Qin, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 2616.

https://doi.org/10.1182/blood-2019-126938

Published: 2019

NARROW

The Well Tolerated VA-Based Regimen Bringing to High Quality of Life Did Not Absolutely Inferior to Intensive Chemotherapy in AML Patients with NPM1 Mutation

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival

Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study

Prolonged Use of Eltrombopag in Patients with Severe Aplastic Anemia without Complete Response at 6 Months after Immunosuppressive Therapy

Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study

Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion

Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience

Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy

Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia

The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study

Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes

Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only